Helixtalk - Rosalind Franklin University's College Of Pharmacy Podcast

In this episode, we interview Brad Cannon, PharmD regarding his career path in pharmacy and his viewpoints on the pharmacy profession.

In this episode, we discuss the optimal drug therapy for three different case vignettes -- depression, hypertension, and diabetes mellitus.

In this episode, we review historical and new treatment options for hepatitis C, including: peginterferon, rivabirin, boceprevir, telaprevir, sofosbuvir (Sovaldi), simeprevir (Olysio), ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak), and ledipasvir/sofosbuvir (Harvoni). May 18, 2015 - Correction added in the beginning of the episode regarding Viekira Pak dosing regimen.

In this episode, we discuss the pharmacology of oversedation, the importance of sedation minimization strategies in mechanically ventilated patients, and overview the sedatives and analgesics commonly used in this patient population.

In this episode, we discuss risk factors for opioid-related adverse events, naloxone (Narcan, Evzio), and a number of non-narcotic agents for neuropathic pain.

In this episode, we summarize and discuss the clinical implications of the SMART trial (Salmeterol Multicenter Asthma Research Trial; Nelson et al, 2006).

In this episode, we discuss two controversial topics in the world of immunizations with Dr. Angelo -- the "high-dose" influenza vaccine and the expanded use of PCV13 (Prevnar-13).

In this episode, we review HIV therapy with Dr. Cottreau with a particular focus on Truvada, Atripla, Complera, Stribild, and Triumeq.

In this episode, we discuss the management of overactive bladder, including: oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), trospium (Sanctura), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq), and onabotulinumtoxinA (Botox).

In this episode, we discuss newly approved agents for diabetes mellitus: Afrezza (inhaled human insulin), SGLT2 inhibitors (Invokana, Farxiga, Jardiance), and long-acting GLP-1 agonists (Bydureon, Tanzeum).

In this episode, we review a wide variety of cancer screening guidelines with a particular focus on the two most controversial screening areas: breast cancer screening with mammography and prostate cancer screening with PSA levels.

In this episode, we have a roundtable discussion regarding ASHP Midyear and the process of pursuing a pharmacy residency program.

In this episode, we discuss the new 2013 ACC/AHA obesity guidelines with a particular focus on three medications for obesity: lorcaserin (Belviq), phentermine/topiramate (Qsymia), and orlistat (Xenical, Alli).

In this episode, we review the National Osteoporosis Foundation's osteoporosis guidelines with a particular focus on two newer agents, denosumab (Prolia) and teriparatide (Forteo).

In this episode, we discuss Bordetella pertussis (whooping cough) with Dr. Michael Fennewald.

In this episode, we discuss our clinical "pet peeves" covering allergy histories, creatinine clearance, surrogate endpoints, "me too" enantiomer drugs, and dose-dependent pharmacology of psychiatric medications.

In this episode, we discuss the pharmacology of the renin-angiotensin-aldosterone system and review the evidence for combining ACE-Is, ARBs, and/or DRIs.

In this episode, we discuss the 2005 ATS/IDSA Healthcare-Associated, Hospital-Acquired, and Ventilator-Associated Pneumonia Guidelines (HCAP, HAP, VAP).

In this episode, we discuss the 2007 ATS/IDSA Community-Acquired Pneumonia (CAP) guidelines.

In this episode, we discuss updates to the GOLD guidelines for COPD and review the newer agents for COPD including roflumilast (Daliresp), indacaterol (Arcapta Neohaler), aclidinium (Tudorza Pressair), umeclidinium/vilanterol (Anoro Ellipta), and fluticasone/vilanterol (Breo Ellipta).